---
title: "Near-point-of-care CRP and SAA meet WHO target product profile for TB screening"
id: "medrxiv-4-near-point-of-care-c-reactive-protein-and-serum-amyloid-a-test-met-who-target"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-4-near-point-of-care-c-reactive-protein-and-serum-amyloid-a-test-met-who-target"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1?rss=1"
published_at: "2026-11-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Near-point-of-care CRP and SAA meet WHO target product profile for TB screening
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-4-near-point-of-care-c-reactive-protein-and-serum-amyloid-a-test-met-who-target
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1?rss=1)
- **Published At:** 2026-11-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The investigators evaluated archived serum from three groups: bacteriology-confirmed symptomatic TB (n=57), probable TB (n=56), and healthy controls (n=60). - Biomarkers measured: **C-reactive protein (CRP)** and **serum amyloid A (SAA)** by near point-of-care fluorescence immunoassay (NPOCT-FIA); **IP-10** measured by ELISA. - The study design was cross-sectional diagnostic testing using stored samples; the source did not report prospective screening implementation details. - ROC analysis produced high AUCs for SAA (AUC 0.961) and CRP (AUC 0.953) when identifying confirmed TB versus probable TB plus healthy controls. - Reported diagnostic thresholds: SAA cut-off >31.0 mg/L, CRP cut-off 21.3 mg/L. - At those thresholds the cohort showed identical sensitivity for SAA and CRP: 96.5% sensitivity. - Specificity differed modestly: SAA 88.6% specificity; CRP 86.0% specificity. - Combining **CRP** and **SAA** yielded 100.0% sensitivity and 83.3% specificity in this sample set. - **IP-10** performed poorly for TB discrimination (AUC 0.545). - Authors reported that **SAA** and **CRP** met the **WHO target product profile** criteria for triage screening; the article is a preprint and not peer reviewed. - Ethical approvals were obtained from local institutional review boards; all data are available on request according to authors.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=qbenNFA62w8rVwBV0B52Y6PMyk2MSMMcD.RMjkwMA94-1794427549.9938862-1.2.1.1-N7lYB1Utj9ptErTbGUr85IvIBYGF704JTzWr0DqSHba9NBfCif0Fov8T.q7KpR.y) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Near point of care C-Reactive Protein and Serum Amyloid-A Test met WHO target product profile for TB screening [ View ORCID Profile](http://orcid.org/0000-0002-3252-1201)Todia Pediatama Setiabudiawan, Nadya Iswandari, [ View ORCID Profile](http://orcid.org/0000-0002-4457-1767)Marcellus Korompis, Raspati Cundarani Koesoemadinata, Evan Susandi, Iceu D Kulsum, Dewi K Turbawaty, Bachti Alisjahbana doi: https://doi.org/10.64898/2026.11.10.26367691 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Todia Pediatama Setiabudiawan 1 Research Center for Care and Control of Infectious Diseases, Universitas Padjadjaran, Bandung, Indonesia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Todia%2BPediatama%2BSetiabudiawan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Setiabudiawan%20TP&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATodia%2BPediatama%2BSetiabudiawan%2B) * [ORCID record for Todia Pediatama Setiabudiawan](http://orcid.org/0000-0002-3252-1201 "Open in new tab") * For correspondence: todia.setiabudiawan@radboudumc.nl Nadya Iswandari 2 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran / Hasan Sadikin General Hospital, Bandung, Indonesia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nadya%2BIswandari%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Iswandari%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANadya%2BIswandari%2B) Marcellus Korompis 3 Research Center for Care and Control of Infectious Diseases, Universitas Padjadjaran, Bandung, Indonesia.; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Marcellus%2BKorompis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Korompis%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMarcellus%2BKorompis%2B) * [ORCID record for Marcellus Korompis](http://orcid.org/0000-0002-4457-1767 "Open in new tab") Raspati Cundarani Koesoemadinata 4 Universitas Pendidikan Indonesia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Raspati%2B%2BCundarani%2BKoesoemadinata%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Koesoemadinata%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARaspati%2B%2BCundarani%2BKoesoemadinata%2B) Evan Susandi 2 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran / Hasan Sadikin General Hospital, Bandung, Indonesia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Evan%2BSusandi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Susandi%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEvan%2BSusandi%2B) Iceu D Kulsum 2 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran / Hasan Sadikin General Hospital, Bandung, Indonesia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Iceu%2BD%2BKulsum%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kulsum%20ID&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIceu%2BD%2BKulsum%2B) Dewi K Turbawaty 5 Department of Clinical Pathology, Faculty of Medicine, Padjadjaran University/Dr. Hasan Sadikin Hospital Bandung * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dewi%2BK%2BTurbawaty%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Turbawaty%20DK&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADewi%2BK%2BTurbawaty%2B) Bachti Alisjahbana 2 Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran / Hasan Sadikin General Hospital, Bandung, Indonesia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Bachti%2BAlisjahbana%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Alisjahbana%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABachti%2BAlisjahbana%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1342507/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1342507/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1342507/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1342507/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1342507/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: TB eradication strategies in high burden countries need affordable, scalable, and accessible screening tools. This study investigated the diagnostic accuracy of C-reactive protein (CRP), serum amyloid A (SAA), and interferon gamma-induced protein 10 (IP-10) as potential screening tools. Methods. This cross-sectional diagnostic study investigated stored archived serum samples from three groups of subjects; bacteriology confirmed symptomatic TB group (n=57), probable TB (n=56) and healthy controls (n=60). CRP and SAA concentrations were measured using near point-of-care fluorescence immunoassay (NPOCT-FIA), while IP-10 was measured using enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of individual and combined biomarkers was evaluated Results Receiver operating characteristic analysis demonstrated excellent diagnostic performance of serum amyloid A (SAA) and C-reactive protein (CRP) for identifying confirmed tuberculosis (TB). Compared with probable TB and healthy controls, SAA achieved an AUC of 0.961 (cut-off >31.0 mg/L), with 96.5% sensitivity and 88.6% specificity, while CRP achieved an AUC of 0.953 (cut-off 21.3 mg/L), with 96.5% sensitivity and 86.0% specificity. Interferon gamma-induced protein 10 (IP-10) showed poor discrimination (AUC 0.545). Combined CRP and SAA achieved 100.0% sensitivity and 83.3% specificity. Conclusion: SAA and CRP met WHO target product profile criteria for TB triage screening. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Health Research Ethics Committee of Dr. Hasan Sadikin General Hospital, Bandung, Indonesia gave ethical approval for this work. The Health Research Ethics Committee of Universitas Padjadjaran, Bandung, Indonesia gave ethical approval for the EVIDENT study and for the COVID-19 vaccine study, from which the archived serum samples were obtained. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.11.26367301v1 "Dysregulated B Cell Education Drives Autoimmunity and Immunodeficiency in Down Syndrome")[Next ](https://www.medrxiv.org/content/10.64898/2026.11.10.26367591v1 "Early Prediction of Discharge Outcomes in Geriatric Rehabilitation: Development and Temporal Validation of a Multiclass Model") Posted November 11, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/11/2026.11.10.26367691.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.10.26367691v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/11/2026.11.10.26367691.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Near point of care C-Reactive Protein and Serum Amyloid-A Test met WHO target product profile for TB screening Todia Pediatama Setiabudiawan, Nadya Iswandari, Marcellus Korompis, Raspati Cundarani Koesoemadinata, Evan Susandi, Iceu D Kulsum, Dewi K Turbawaty, Bachti Alisjahbana medRxiv 2026.11.10.26367691; doi: https://doi.org/10.64898/2026.11.10.26367691 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.10.26367691v1%26text%3DNear%2520point%2520of%2520care%2520C-Reactive%2520Protein%2520and%2520Serum%2520Amyloid-A%2520Test%2520met%2520WHO%2520target%2520product%2520profile%2520for%2520TB%2520screening "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.10.26367691v1%26t%3DNear%2520point%2520of%2520care%2520C-Reactive%2520Protein%2520and%2520Serum%2520Amyloid-A%2520Test%2520met%2520WHO%2520target%2520product%2520profile%2520for%2520TB%2520screening "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.10.26367691v1%26title%3DNear%2520point%2520of%2520care%2520C-Reactive%2520Protein%2520and%2520Serum%2520Amyloid-A%2520Test%2520met%2520WHO%2520target%2520product%2520profile%2520for%2520TB%2520screening%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.10.26367691v1%26title%3DNear%2520point%2520of%2520care%2520C-Reactive%2520Protein%2520and%2520Serum%2520Amyloid-A%2520Test%2520met%2520WHO%2520target%2520product%2520profile%2520for%2520TB%2520screening "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.10.26367691) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.10.26367691v1&count=horizontal&via=&text=Near%20point%20of%20care%20C-Reactive%20Protein%20and%20Serum%20Amyloid-A%20Test%20met%20WHO%20target%20product%20profile%20for%20TB%20screening&counturl=www.medrxiv.org/content/10.64898/2026.11.10.26367691v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (638) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (920) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (352) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5017) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (429) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (679) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1696) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16282) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (36) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1242) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7290) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (753) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1095) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5304) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1474) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1836) * [Hematology](https://www.medrxiv.org/collection/hematology) (599) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1383) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16501) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1203) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (701) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (157) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (754) * [Neurology](https://www.medrxiv.org/collection/neurology) (7616) * [Nursing](https://www.medrxiv.org/collection/nursing) (380) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1132) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1296) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1041) * [Oncology](https://www.medrxiv.org/collection/oncology) (3751) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1096) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (411) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (466) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (502) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (143) * [Pathology](https://www.medrxiv.org/collection/pathology) (722) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1864) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (757) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (787) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6150) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (10011) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2540) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1524) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (127
## Related Clinical Research

- [SARS-CoV-2 antibody landscape after multiple Omicron-era vaccinations and infections](https://medichelpline.com/clinical-feed/medrxiv-23-sars-cov-2-antibody-landscape-following-multiple-vaccinations-and-infections.md)
- [Self-reported tuberculosis prevalence and vulnerability factors in six rural Indian districts](https://medichelpline.com/clinical-feed/plos-one-16-self-reported-prevalence-of-tuberculosis-and-selected-associated-vulnerability.md)
- [ACE2 Polymorphisms rs2285666 and rs147311723 Linked to Inflammation in COVID‑19 and TB Co‑infection](https://medichelpline.com/clinical-feed/medrxiv-21-ace2-polymorphisms-rs2285666-and-rs147311723-are-clinically-relevant-variants.md)
- [Burden of RSV Hospitalizations in Brazilian Adults Aged ≥60 Years (2013–2024)](https://medichelpline.com/clinical-feed/pubmed-42758792.md) (DOI: 10.1371/journal.pone.0357303)
- [Leveraging MAHA and Kennedy to Combat Measles Vaccine Hesitancy](https://medichelpline.com/clinical-feed/stat-news-0-opinion-how-kennedy-and-maha-could-help-stop-measles.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.